Korean Consensus Criteria for the Severity Classification of Alopecia Areata
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: A set of criteria for severity classification is essential in alopecia areata (AA). Cur- rently, no guidelines are universally accepted for defining AA severity. Objective: This study aimed to establish a set of consensus criteria for classif ying the severity of and identif ying treatment refractoriness in AA. Methods: A preliminar y draft of the definition for moderate-to-severe AA was crafted based on available evidence, and members of the Korean Hair Research Society (KHRS) subsequently endorsed the recommendation through an online sur vey. Results: In the first Delphi round, consensus was attained on 15 questions. After refining cer- tain items in the second round, consensus was achieved on 23 out of 26 questions. The KHRS first defined AA severity using the severity of alopecia tool (SALT). SALT ≥50 was defined as severe, 20≤ SALT <50 as moderate, and SALT <20 as mild. Moderate AA was considered severe if it meets one or more of the following criteria: dermatology life quality index >10, presence of accompanying eyebrow or eyelash loss, positive hair loss activity, or treatment-refractor y AA. Conclusion: These consensus criteria can help clinicians accurately diagnose AA, provide appro- priate treatment, and monitor its progression.
Abstract
Background: A set of criteria for severity classification is essential in alopecia areata (AA). Cur- rently, no guidelines are universally accepted for defining AA severity. Objective: This study aimed to establish a set of consensus criteria for classif ying the severity of and identif ying treatment refractoriness in AA. Methods: A preliminar y draft of the definition for moderate-to-severe AA was crafted based on available evidence, and members of the Korean Hair Research Society (KHRS) subsequently endorsed the recommendation through an online sur vey. Results: In the first Delphi round, consensus was attained on 15 questions. After refining cer- tain items in the second round, consensus was achieved on 23 out of 26 questions. The KHRS first defined AA severity using the severity of alopecia tool (SALT). SALT ≥50 was defined as severe, 20≤ SALT <50 as moderate, and SALT <20 as mild. Moderate AA was considered severe if it meets one or more of the following criteria: dermatology life quality index >10, presence of accompanying eyebrow or eyelash loss, positive hair loss activity, or treatment-refractor y AA. Conclusion: These consensus criteria can help clinicians accurately diagnose AA, provide appro- priate treatment, and monitor its progression.
참고문헌 (43)
- Strazzulla LC, "Alopecia areata : disease characteristics, clinical evaluation, and new perspectives on pathogenesis", J Am Acad Dermatol, 78, pp.1~12 (2018)
- Strazzulla LC, "Alopecia areata : an appraisal of new treatment approaches and overview of current therapies", J Am Acad Dermatol, 78, pp.15~24 (2018)
- Park H, "Guidelines for the management of patients with alopecia areata in Korea : part I topical and device-based treatment", Ann Dermatol, 35, pp.190~204 (2023)
- King BA, "Defining severity in alopecia areata : current perspectives and a multidimensional framework", Dermatol Ther(Heidelb), 12, pp.825~834 (2022)
- Cranwell WC, "Treatment of alopecia areata : an Australian expert consensus statement", Australas J Dermatol, 60, pp.163~170 (2019)
- Rossi A, "Italian guidelines in diagnosis and treatment of alopecia areata", G Ital Dermatol Venereol, 154, pp.609~623 (2019)
- Fukuyama M, "Alopecia areata : current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines", J Dermatol, 49, pp.19~36 (2022)
- Messenger AG, "British Association of Dermatologists’ guidelines for the management of alopecia areata 2012", Br J Dermatol, 166, pp.916~926 (2012)
- King BA, "Development of the alopecia areata scale for clinical use : results of an academic-industry collaborative effort", J Am Acad Dermatol, 86, pp.359~364 (2022)
- Wyrwich KW, "The alopecia areata investigator global assessment scale : a measure for evaluating clinically meaningful success in clinical trials", Br J Dermatol, 183, pp.702~709 (2020)
- Wyrwich KW, "Development of clinician-reported outcome(ClinRO)and patient-reported outcome(PRO)measures for eyebrow, eyelash and nail assessment in alopecia areata", Am J Clin Dermatol, 21, pp.725~732 (2020)
- Wuestefeld A, "Towards reporting guidelines of research using whole-body vibration as training or treatment regimen in human subjects-A Delphi consensus study", PLoS One, 15, pp.e0235905~ (2020)
- Lin YK, "Development and pilot testing of an informed consent video for patients with limb trauma prior to debridement surgery using a modified Delphi technique", BMC Med Ethics, 18, pp.67~ (2017)
- Kim SH, "Healthcare policy agenda for a sustainable healthcare system in Korea : building consensus using the Delphi method", J Korean Med Sci, 37, pp.e284~ (2022)
- Guyatt GH, "GRADE guidelines : 2. Framing the question and deciding on important outcomes", J Clin Epidemiol, 64, pp.395~400 (2011)
- Bernardis E, "Pediatric severity of alopecia tool", Pediatr Dermatol, 35, pp.e68~e69 (2018)
- Meah N, "The alopecia areata consensus of experts(ACE)study : results of an international expert opinion on treatments for alopecia areata", J Am Acad Dermatol, 83, pp.123~130 (2020)
- Ramos PM, "Consensus on the treatment of alopecia areata-Brazilian Society of Dermatology", An Bras Dermatol, 95(Suppl 1), pp.39~52 (2020)
- Tsuboi R, "Japanese Dermatological Association’s guidelines for the management of alopecia areata", Nihon Hifuka Gakkai Zasshi, 127, pp.2741~2762 (2017)
- Olsen E, "Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation", J Am Acad Dermatol, 40, pp.242~246 (1999)
- Toussi A, "Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata : a systematic review", J Am Acad Dermatol, 85, pp.162~175 (2021)
- van Dalen M, "Anxiety, depression, and quality of life in children and adults with alopecia areata : a systematic review and meta-analysis", Front Med(Lausanne), 9, pp.1054898~ (2022)
- Liu LY, "Health-related quality of life(HRQoL)among patients with alopecia areata(AA) : a systematic review", J Am Acad Dermatol, 75, pp.806~812 (2016)
- Hongbo Y, "Translating the science of quality of life into practice : what do dermatology life quality index scores mean?", J Invest Dermatol, 125, pp.659~664 (2005)
- Hunt N, "The psychological impact of alopecia", BMJ, 331, pp.951~953 (2005)
- Liu LY, "Eyebrows are important in the treatment of alopecia areata", J Investig Dermatol Symp Proc, 20, pp.S37~S40 (2020)
- King B, "Two phase 3 trials of baricitinib for alopecia areata", N Engl J Med, 386, pp.1687~1699 (2022)
- Lai VWY, "Cyclosporine for moderate-to-severe alopecia areata : a double-blind, randomized, placebo-controlled clinical trial of efficacy and safety", J Am Acad Dermatol, 81, pp.694~701 (2019)
- Manjaly P, "Development and validation of the Brigham Eyelash Tool for Alopecia(BELA) : a measure of eyelash alopecia areata", J Am Acad Dermatol, 85, pp.271~272 (2021)
- Tkachenko E, "Brigham Eyebrow Tool for Alopecia : a reliable assessment of eyebrow alopecia areata", J Investig Dermatol Symp Proc, 20, pp.S41~S44 (2020)
- Jang YH, "Alopecia areata progression index, a scoring system for evaluating overall hair loss activity in alopecia areata patients with pigmented hair : a development and reliability assessment", Dermatology, 232, pp.143~149 (2016)
- McDonald KA, "Hair pull test : evidence-based update and revision of guidelines", J Am Acad Dermatol, 76, pp.472~477 (2017)
- Inui S, "Clinical significance of dermoscopy in alopecia areata : analysis of 300 cases", Int J Dermatol, 47, pp.688~693 (2008)
- Guttman-Yassky E, "Phase 2a randomized clinical trial of dupilumab(anti-IL-4Rα)for alopecia areata patients", Allergy, 77, pp.897~906 (2022)
- King B, "A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata : 24-week results", J Am Acad Dermatol, 85, pp.379~387 (2021)
- Olsen EA, "Ruxolitinib cream for the treatment of patients with alopecia areata : a 2-part, double-blind, randomized, vehicle-controlled phase 2 study", J Am Acad Dermatol, 82, pp.412~419 (2020)
- Kagami S, "Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata", J Cosmet Dermatol, 19, pp.2411~2414 (2020)
- Yan D, "The efficacy and safety of JAK inhibitors for alopecia areata : a systematic review and meta-analysis of prospective studies", Front Pharmacol, 13, pp.950450~ (2022)
- Nowaczyk J, "Cyclosporine with and without systemic corticosteroids in treatment of alopecia areata : a systematic review", Dermatol Ther(Heidelb), 10, pp.387~399 (2020)
- Husein-ElAhmed H, "Efficacy and predictive factors of cyclosporine A in alopecia areata : a systematic review with meta-analysis", J Dermatolog Treat, 33, pp.1643~1651 (2022)
- Phan K, "Methotrexate for alopecia areata : a systematic review and meta-analysis", J Am Acad Dermatol, 80, pp.120~127 (2019)
- Smith A, "High relapse rates despite early intervention with intravenous methylprednisolone pulse therapy for severe childhood alopecia areata", Pediatr Dermatol, 32, pp.481~487 (2015)
- Chiang KS, "clinical efficacy of diphenylcyclopropenone in alopecia areata : retrospective data analysis of 50 patients", J Investig Dermatol Symp Proc, 17, pp.50~55 (2015)